Show simple item record

dc.contributor.authorMoor, Rebecca Jane
dc.contributor.authorRoberts, Kate Elizabeth
dc.contributor.authorMason, Robert
dc.contributor.authorGunawan, Ben
dc.contributor.authorFeng, Sophie
dc.contributor.authorHong, Jun Hee
dc.contributor.authorVon Itzstein, Mitchell
dc.contributor.authorHughes, Brett Gordon Maxwell
dc.contributor.authorLwin, Zarnie
dc.contributor.authorJain, Vikram Kumar
dc.contributor.authorBigby, Kieron James
dc.contributor.authorAzer, Mary WF
dc.contributor.authorSanmugarajah, Jasotha
dc.contributor.authorO'Byrne, Kenneth John
dc.date.accessioned2021-02-26T00:51:26Z
dc.date.available2021-02-26T00:51:26Z
dc.date.issued2018
dc.identifier.issn0732-183X
dc.identifier.doi10.1200/JCO.2018.36.15_suppl.9067
dc.identifier.urihttp://hdl.handle.net/10072/402628
dc.description.abstractBackground: Immune checkpoint inhibitors are routinely used in Non Small Cell Lung Cancer (NSCLC) patients following progression on first-line therapy. Immune-related Adverse Events (IrAEs) have been associated with the efficacy of PD-1 inhibitors in melanoma. The association between the development of IrAEs and efficacy of nivolumab remains unclear in NSCLC. Methods: We retrospectively collected data from patients who received nivolumab for advanced NSCLC on an Open Access Program across seven oncology institutions in Queensland, Australia, and analyzed whether there was an association between outcomes and the development of immune-related toxicity. Results: One hundred and ninety six patients were enrolled to this ethics committee approved audit – 77 females (39%) and 119 (61%) males; PS 0-1 (62%); PS 2-3 (38%); median age 67 (range 42-84). An objective response was recorded in 24% of patients; partial response (47/196) with one complete response, in addition 28% (55/196) had stable disease. The median overall survival was 9.2 months; 13.4 months in PS 0-1 patients and 4.2 months in PS 2-3 patients. At 1 year, the overall survival rate was 42%; 57% in patients with PS 0-1 and 18% in PS 2-3 patients. The presence of IrAEs of any grade occurred in 36% of patients and was associated with a longer median PFS of 5.9 months versus 2.3 months (P value < 0.01, 95% CI) in patients with no immune toxicity on Kaplan Meier analysis. The median OS of patients experiencing an IrAE was 24.3 months compared with 6.5 months without (P value < 0.01, 95% CI). A durable clinical benefit was observed in 72% of patients who developed at least one IrAE versus 37% in those without any immune mediated toxicity. Analysis of the prognostic relevance of routine histological, hematological and biochemical parameters is ongoing with a multivariate analysis planned. Conclusions: Nivolumab had clinically significant long-term benefits in the treatment of locally advanced and metastatic NSCLC with 12 month survival rates in keeping with clinical trials in PS 0-1 patients. The development of IrAEs was associated with improved outcomes including median PFS, OS and higher rates of clinical response in this cohort.
dc.languageEnglish
dc.publisherAmerican Society of Clinical Oncology (ASCO)
dc.relation.ispartofconferencenameASCO Annual Meeting
dc.relation.ispartofconferencetitleJournal of Clinical Oncology
dc.relation.ispartofdatefrom2018-06-01
dc.relation.ispartofdateto2018-06-05
dc.relation.ispartoflocationChicago, Illinois, USA
dc.relation.ispartofissue15
dc.relation.ispartofvolume36
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3211
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.titleImmune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationMoor, RJ; Roberts, KE; Mason, R; Gunawan, B; Feng, S; Hong, JH; Von Itzstein, M; Hughes, BGM; Lwin, Z; Jain, VK; Bigby, KJ; Azer, MWF; Sanmugarajah, J; O'Byrne, KJ, Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study, Journal of Clinical Oncology, 2018, 36 (15)
dc.date.updated2021-02-26T00:43:27Z
gro.hasfulltextNo Full Text
gro.griffith.authorVon Itzstein, Mitchell S.
gro.griffith.authorAzer, Mary


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record